医学
间皮素
抗体-药物偶联物
药品
妇科癌症
肿瘤科
抗体
药物开发
癌症
内科学
癌症研究
卵巢癌
药理学
免疫学
单克隆抗体
作者
Elizabeth K. Lee,Joyce F. Liu
标识
DOI:10.1016/j.ygyno.2019.03.245
摘要
Antibody drug conjugates (ADCs) are an exciting class of oncologic therapeutics. ADCs have been FDA approved in hematologic malignancies and breast cancer and are a growing area of study in numerous solid malignancies. The desire for tumor-specific therapies with decreased systemic toxicity has driven over a decade of research into the design and optimization of ADCs, which are now in a third generation of development. Gynecologic malignancies in particular suffer a dearth of novel therapies. This review will examine the field of ADCs in gynecologic cancers, focusing on ADCs targeting folate receptor alpha (FRα), mesothelin, tissue factor, MUC16 (CA125), NaPi2B, and Trop2.
科研通智能强力驱动
Strongly Powered by AbleSci AI